These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 20670140)
1. Revisiting chordoma with brachyury, a "new age" marker: analysis of a validation study on 51 cases. Jambhekar NA; Rekhi B; Thorat K; Dikshit R; Agrawal M; Puri A Arch Pathol Lab Med; 2010 Aug; 134(8):1181-7. PubMed ID: 20670140 [TBL] [Abstract][Full Text] [Related]
2. Patterns of brachyury expression in chordomas. Dridi M; Boutonnat J; Dumollard JM; Peoc'h M; Karpathiou G Ann Diagn Pathol; 2021 Aug; 53():151760. PubMed ID: 33989961 [TBL] [Abstract][Full Text] [Related]
3. Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas. Wang K; Tian K; Wang L; Wu Z; Ren C; Hao S; Feng J; Li J; Wan H; Jia G; Zhang L; Zhang J Mol Med Rep; 2015 Sep; 12(3):4298-4304. PubMed ID: 26099340 [TBL] [Abstract][Full Text] [Related]
4. Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis. Oakley GJ; Fuhrer K; Seethala RR Mod Pathol; 2008 Dec; 21(12):1461-9. PubMed ID: 18820665 [TBL] [Abstract][Full Text] [Related]
5. Chordoma: Immunohistochemical Analysis of Brachury. Sun HI; Guduk M; Gucyetmez B; Yapicier O; Pamir MN Turk Neurosurg; 2018; 28(2):174-178. PubMed ID: 28094431 [TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic features of four rare types of chordomas, confirmed by brachyury immunostaining. Rekhi B; Banerjee D; Ramadwar M; Bajpai J; Jambhekar NA Indian J Pathol Microbiol; 2017; 60(3):350-354. PubMed ID: 28937370 [TBL] [Abstract][Full Text] [Related]
7. Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma. Zhang L; Guo S; Schwab JH; Nielsen GP; Choy E; Ye S; Zhang Z; Mankin H; Hornicek FJ; Duan Z PLoS One; 2013; 8(9):e75851. PubMed ID: 24086644 [TBL] [Abstract][Full Text] [Related]
8. Classic chordoma coexisting with benign notochordal cell rest demonstrating different immunohistological expression patterns of brachyury and galectin-3. Shen J; Li CD; Yang HL; Lu J; Zou TM; Wang DL; Deng M J Clin Neurosci; 2011 Jan; 18(1):96-9. PubMed ID: 20855213 [TBL] [Abstract][Full Text] [Related]
9. Diagnosing an extra-axial chordoma of the proximal tibia with the help of brachyury, a molecule required for notochordal differentiation. O'donnell P; Tirabosco R; Vujovic S; Bartlett W; Briggs TW; Henderson S; Boshoff C; Flanagan AM Skeletal Radiol; 2007 Jan; 36(1):59-65. PubMed ID: 16810540 [TBL] [Abstract][Full Text] [Related]
10. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. Vujovic S; Henderson S; Presneau N; Odell E; Jacques TS; Tirabosco R; Boshoff C; Flanagan AM J Pathol; 2006 Jun; 209(2):157-65. PubMed ID: 16538613 [TBL] [Abstract][Full Text] [Related]
11. T gene isoform expression pattern is significantly different between chordomas and notochords. Wang K; Hu Q; Wang L; Chen W; Tian K; Cao C; Wu Z; Jia G; Zhang L; Zeng C; Zhang J Biochem Biophys Res Commun; 2015 Nov; 467(2):261-7. PubMed ID: 26435504 [TBL] [Abstract][Full Text] [Related]
12. Specificity of brachyury in the distinction of chordoma from clear cell renal cell carcinoma and germ cell tumors: a study of 305 cases. Sangoi AR; Karamchandani J; Lane B; Higgins JP; Rouse RV; Brooks JD; McKenney JK Mod Pathol; 2011 Mar; 24(3):425-9. PubMed ID: 21102418 [TBL] [Abstract][Full Text] [Related]
13. Brachyury expression in intracranial SMARCB1-deficient tumors: important points for distinguishing poorly differentiated chordoma from atypical teratoid/rhabdoid tumor. Kohashi K; Yamamoto H; Yamada Y; Kinoshita I; Oda Y Hum Pathol; 2021 Jun; 112():1-8. PubMed ID: 33741347 [TBL] [Abstract][Full Text] [Related]
14. Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis. Kitamura Y; Sasaki H; Kimura T; Miwa T; Takahashi S; Kawase T; Yoshida K J Neuropathol Exp Neurol; 2013 Sep; 72(9):816-23. PubMed ID: 23965741 [TBL] [Abstract][Full Text] [Related]
15. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Tirabosco R; Mangham DC; Rosenberg AE; Vujovic S; Bousdras K; Pizzolitto S; De Maglio G; den Bakker MA; Di Francesco L; Kalil RK; Athanasou NA; O'Donnell P; McCarthy EF; Flanagan AM Am J Surg Pathol; 2008 Apr; 32(4):572-80. PubMed ID: 18301055 [TBL] [Abstract][Full Text] [Related]
16. Chordomas: A review with emphasis on their pathophysiology, pathology, molecular biology, and genetics. Karpathiou G; Dumollard JM; Dridi M; Dal Col P; Barral FG; Boutonnat J; Peoc'h M Pathol Res Pract; 2020 Sep; 216(9):153089. PubMed ID: 32825957 [TBL] [Abstract][Full Text] [Related]
17. New Prospects for Molecular Targets for Chordomas. Ozair MZ; Shah PP; Mathios D; Lim M; Moss NS Neurosurg Clin N Am; 2020 Apr; 31(2):289-300. PubMed ID: 32147018 [TBL] [Abstract][Full Text] [Related]
18. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma. Otani R; Mukasa A; Shin M; Omata M; Takayanagi S; Tanaka S; Ueki K; Saito N J Neurosurg; 2018 May; 128(5):1428-1437. PubMed ID: 28753115 [TBL] [Abstract][Full Text] [Related]
19. Brachyury: a diagnostic marker for the differential diagnosis of chordoma and hemangioblastoma versus neoplastic histological mimickers. Barresi V; Ieni A; Branca G; Tuccari G Dis Markers; 2014; 2014():514753. PubMed ID: 24591762 [TBL] [Abstract][Full Text] [Related]
20. Notochordal Tumors: An Update on Molecular Pathology with Therapeutic Implications. Yamaguchi T; Imada H; Iida S; Szuhai K Surg Pathol Clin; 2017 Sep; 10(3):637-656. PubMed ID: 28797506 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]